Search other companies ESG researched by sustainAX here
Alzecure Pharma – ESG risk research and ESG rating
We at sustainAX have ESG risk researched and ESG risk rated Alzecure Pharma and our clients can access the reseach on their Bloomberg terminals.
Alzecure Pharma is in the materiality based sector of PHARMA, BIOTECH AND LIFE SCIENCES.
Our ESG risk research of Alzecure Pharma
Our approach to ESG research is fundamental, that means that we have studied all relevant publications by Alzecure Pharma and combined this with fundamental understanding of ESG challenges and risks of different activities and for the PHARMA, BIOTECH AND LIFE SCIENCES sector. This makes us well placed to estimate the ESG risks of Alzecure Pharma. We have published a 33 pages ESG research report on Alzecure Pharma with a conclusion highlighting the most important residual risks, a section suggesting how it should be integrated in investment decisions and a list of all the questions we think should be asked to Alzecure Pharma.
More about our ESG risk research here: https://www.sustainax.com/index.php/esg-research/
AGGREGATED ESG RISK RATING* for Alzecure Pharma:
40-60 of 100
Middle risk
Where 100 is the lowest ESG risk and 0 is the highest risk.
*The ESG, E, S and G risk rating ranges indicate to what degree Alzecure Pharma has addressed and mitigated their material ESG risks according to the sustainAX materiality matrix. sustainAX’ clients have access to the exact ESG risk rating.
**The weight in the aggregated ESG rating
Environmental RISK RATING* and WEIGHT** for Alzecure Pharma:
0-20 of 100 – Very High risk
18.99 %
Social RISK RATING* and WEIGHT** for Alzecure Pharma:
40-60 of 100 – Middle risk
34.57 %
Governance RISK RATING* and WEIGHT** for Alzecure Pharma:
40-60 of 100 – Middle risk
46.42 %
About the company:
AlzeCure Pharma develops new drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain, for which currently available treatment is extremely limited. AlzeCure® aims to pursue its own projects through preclinical research and development to an early clinical phase. NeuroRestore® – the platform is developing a new generation of symptom-relieving drugs for the treatment of illnesses with cognitive disorders, such as Alzheimer’s disease. Alzstatin® – the platform develops innovative disease-modifying and preventive drugs for Alzheimer’s disease. Painless – two projects: TrkA-NAM and ACD440, which both focus on severe pain.
Are you interested in the ESG research and ESG rating?
If you are interested in the ESG risk research and ESG risk rating of Alzecure Pharma, contact us at sustainAX!
© Copyright SustainAX AB and www.sustainax.com, 2024. Please note that by accessing and using the SustainAX AB website, you are consenting to comply with our Terms of Use and acknowledging the acceptance of any inherent risks. The content provided on this site is available for your non-commercial, non-competitive use, specifically for the purposes of understanding companies’ environmental, social, and governance (ESG) risks. Should you wish to employ our information within a professional capacity, it is incumbent upon you to secure the appropriate licensing rights from us. Be aware that any form of unauthorised data extraction or the systematic electronic harvesting of our content is expressly forbidden.